Celltrion announced on the 3rd that Remicade biosimilar Remsima has been licensed in 100 global countries 10 years after its domestic approval in 2012. Remsima is a biosimilar of TNF-억제 inhibitors used to treat autoimmune diseases such as rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, Crohn's disease, psoriasis.

It started developing materials in 2006 and obtained permission from the Ministry of Food and Drug Safety for the first time in the world in July 2012. It was licensed in Europe in September 2013 and in the United States in April 2016. It then steadily obtained permits in Canada, Japan, Brazil, Australia, Egypt, and South Africa, and at the end